Results 141 to 150 of about 10,873 (167)

Gender-dependent multiple cross-phenotype association of interferon lambda genetic variants with peripheral blood profiles in healthy individuals. [PDF]

Mol Genet Genomic Med
Roy DG, Singh L, Chaturvedi HK, Chinnaswamy S.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Type III Interferons (Lambda Interferons) in Rheumatic Autoimmune Diseases

Archivum Immunologiae et Therapiae Experimentalis, 2020
The last 2 decades have witnessed the discovery and characterization of a new family of cytokines with immunological characteristics similar to those described for type I interferons, type III or lambda interferons. Unraveling the molecular mechanisms underlying each type of interferon has allowed us to understand how some autoimmune diseases can be ...
Tania Mora-Arias, Luis M. Amezcua-Guerra
openaire   +2 more sources

Interferon Lambda and Liver Fibrosis

Journal of Interferon & Cytokine Research, 2019
Fibrosis is a highly conserved and coordinated wound healing response to injury. In the liver, injury is promoted by immune effector mechanisms that are common across various disease etiologies and even between organs such as lungs, kidneys, heart, and other organs.
Eslam, Mohammed, Ahlenstiel, Golo (R18999), George, Jacob   +2 more
openaire   +3 more sources

Lambda interferons in immunity and autoimmunity

Journal of Autoimmunity, 2019
Type I IFNs are well known players in immunity and autoimmunity. They induce potent innate and adaptive immune responses essential for mediating host defenses against viral and bacterial infections but also driving inflammation during chronic inflammatory and autoimmune diseases.
Stelios, Vlachiotis, Evangelos, Andreakos   +1 more
openaire   +2 more sources

Interferon-lambda serum levels in hepatitis C

Journal of Hepatology, 2011
Dendritic cells (DCs) trigger adaptive immune responses and are an important source of antiviral cytokines. In hepatitis C virus (HCV) infection DC function is markedly impaired. Thus far, studies have focused on types I and II interferon (IFN). We studied IFN-lambda1 (IL-29) and IFN-lambda2/3 (IL-28A/B) serum levels in patients with different outcomes
Bettina, Langhans, Bernd, Kupfer, Ingrid, Braunschweiger, Simone, Arndt, Wibke, Schulte, Hans Dieter, Nischalke, Jacob, Nattermann, Johannes, Oldenburg, Tilman, Sauerbruch, Ulrich, Spengler   +9 more
openaire   +2 more sources

Interferon Lambda: Toward a Dual Role in Cancer

Journal of Interferon & Cytokine Research, 2019
Interferon (IFN)-λ, a type III interferon (IFN), is a member of a new family of pleotropic cytokines that share high similarity with classical IFNs α and β (IFN-α/β), type I IFNs. IFN-λ acts as an antiviral agent and displays distinct biological functions, including tumor suppression.
Ahmed, Lasfar, Andrew, Zloza, Ann W, Silk, Leonard Y, Lee, Karine A, Cohen-Solal   +4 more
openaire   +2 more sources

Antiviral Effect of Interferon Lambda Against Lymphocytic Choriomeningitis Virus

Journal of Interferon & Cytokine Research, 2015
Lambda interferons inhibit replication of many viruses, but their role in the inhibition of lymphocytic choriomeningitis virus (LCMV) infection remains unclear. In this study, we examined the antiviral effects of interferon (IFN)-λ2 and IFN-λ3 against LCMV in A549 cells.
Lubomira, Lukacikova, Ingrid, Oveckova, Tatiana, Betakova, Katarina, Laposova, Katarina, Polcicova, Silvia, Pastorekova, Jaromir, Pastorek, Jana, Tomaskova   +7 more
openaire   +2 more sources

Evolutionary insights of interferon lambda genes in tetrapods

Journal of Evolutionary Biology
Abstract Type III interferon (IFN), also known as IFN-λ, is an innate antiviral protein. We retrieved the sequences of IFN-λ and their receptors from 42 tetrapod species and conducted a computational evolutionary analysis to understand the diversity of these genes.
Devika Gautam, Anil Sindhu, Ashutosh Vats, Shiveeli Rajput, Chanchal Rana, Sachinandan De   +5 more
openaire   +2 more sources

Interferon lambda as a potential treatment for COVID-19

Expert Opinion on Biological Therapy, 2023
Pegylated interferon lambda substantially reduced the risk of COVID-19-related hospitalizations or emergency room visits in a recent phase 3, multi-center, randomized, double-blind, placebo-controlled study of high-risk, non-hospitalized adult patients with SARS-CoV-2 infection compared to treatment with placebo.Interferons are a family of signaling ...
openaire   +2 more sources